470 related articles for article (PubMed ID: 8986453)
1. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Wegner M; Ganten D; Stasch JP
Hypertens Res; 1996 Dec; 19(4):229-38. PubMed ID: 8986453
[TBL] [Abstract][Full Text] [Related]
2. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene.
Stasch JP; Hirth-Dietrich C; Ganten D; Wegner M
Am J Hypertens; 1996 Aug; 9(8):795-802. PubMed ID: 8862226
[TBL] [Abstract][Full Text] [Related]
3. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
Wegner M; Hirth-Dietrich C; Knorr A; Dressel J; Ganten D; Stasch JP
Hypertens Res; 1996 Sep; 19(3):151-9. PubMed ID: 8891743
[TBL] [Abstract][Full Text] [Related]
4. Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs.
Wegner M; Stasch JP; Hirth-Dietrich C; Dressel J; Voges KP; Kazda S
Clin Exp Hypertens; 1995 Aug; 17(6):861-76. PubMed ID: 7581258
[TBL] [Abstract][Full Text] [Related]
5. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of neutral endopeptidase potentiates the effects of atrial natriuretic peptide on acute cyclosporin-induced nephrotoxicity.
Capasso G; Unwin R; Ciani F; Rizzo A; Russo F; Pica A; De Santo NG
Nephron; 2000 Nov; 86(3):298-305. PubMed ID: 11096287
[TBL] [Abstract][Full Text] [Related]
7. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide.
Trapani AJ; Smits GJ; McGraw DE; Spear KL; Koepke JP; Olins GM; Blaine EH
J Cardiovasc Pharmacol; 1989 Sep; 14(3):419-24. PubMed ID: 2476621
[TBL] [Abstract][Full Text] [Related]
8. Effects of a neutral endoprotease enzyme inhibitor, thiorphan, on hemodynamics and renal excretory function in four models of experimental hypertension.
Pamnani MB; Chen S; Bryant HJ; Schooley JF; Haddy FJ; Ghai RD
Clin Exp Hypertens; 2000 Jan; 22(1):45-62. PubMed ID: 10685724
[TBL] [Abstract][Full Text] [Related]
9. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and secretion of natriuretic peptides in the hypertensive TGR(mREN-2)27 transgenic rat.
Marttila M; Vuolteenaho O; Ganten D; Nakao K; Ruskoaho H
Hypertension; 1996 Dec; 28(6):995-1004. PubMed ID: 8952588
[TBL] [Abstract][Full Text] [Related]
11. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment.
Lainchbury JG; Richards AM; Nicholls MG; Espiner EA; Yandle TG
J Clin Endocrinol Metab; 1999 Feb; 84(2):723-9. PubMed ID: 10022444
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
13. Degradation of atrial natriuretic peptide: pharmacologic effects of protease EC 24.11 inhibition.
Webb RL; Yasay GD; McMartin C; McNeal RB; Zimmerman MB
J Cardiovasc Pharmacol; 1989 Aug; 14(2):285-93. PubMed ID: 2476603
[TBL] [Abstract][Full Text] [Related]
14. Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats.
Park KS; Li Y; Zhang Y; Gerbes AL; Liu H; Swain MG; Lee SS
Br J Pharmacol; 2003 May; 139(1):81-8. PubMed ID: 12746226
[TBL] [Abstract][Full Text] [Related]
15. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney.
Roksnoer LCW; Uijl E; de Vries R; Garrelds IM; Jan Danser AH
Eur J Pharmacol; 2018 Apr; 824():128-132. PubMed ID: 29432709
[TBL] [Abstract][Full Text] [Related]
17. Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.
Wilkins MR; Settle SL; Kirk JE; Taylor SA; Moore KP; Unwin RJ
Br J Pharmacol; 1992 Sep; 107(1):50-7. PubMed ID: 1330165
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep.
Charles CJ; Espiner EA; Richards AM; Nicholls MG; Yandle TG
Am J Physiol; 1996 Jun; 270(6 Pt 2):R1324-31. PubMed ID: 8764300
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
